Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product
Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT trial
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product TLX250-CDx
Recommencement of ZIRCON Phase III Trial Recruitment in EU
Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in Europe.
Presentation to Jefferies Virtual Healthcare Conference
Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare Conference
Telix Pharmaceuticals Appoints Dr Colin Hayward as Chief Medical Officer
Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer (CMO).
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29 – 31, 2020. IPAX-1 is a Phase 1/2 clinical study of TLX101 (also known as 131I-IPA or 4-L-[131I]iodo-phenylalanine) for patients with recurrent glioblastoma multiforme (GBM).
Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings Corp
Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study
Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for TLX591